LENSAR Q2 2023 Earnings Report $14.15 +0.02 (+0.14%) As of 11:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast LENSAR EPS ResultsActual EPS-$0.81Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ALENSAR Revenue ResultsActual Revenue$12.01 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALENSAR Announcement DetailsQuarterQ2 2023Date8/9/2023TimeN/AConference Call ResourcesConference CallConference Call TranscriptPress ReleaseLNSR Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Remove Ads LENSAR Earnings HeadlinesLENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSRMarch 26, 2025 | businesswire.comLensar downgraded to Hold from Buy at Lake StreetMarch 26, 2025 | markets.businessinsider.comTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.March 31, 2025 | Porter & Company (Ad)Lake Street Downgrades LENSAR (LNSR)March 25, 2025 | msn.comLENSAR's (LNSR) Hold Rating Reiterated at Lake Street CapitalMarch 25, 2025 | americanbankingnews.comShareholder Alert: The Ademi Firm Investigates Whether LENSAR, Inc. is Obtaining a Fair Price for Its Public ShareholdersMarch 24, 2025 | tmcnet.comSee More LENSAR Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like LENSAR? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LENSAR and other key companies, straight to your email. Email Address About LENSARLENSAR (NASDAQ:LNSR), a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.View LENSAR ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
